Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Eli Lilly and Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and an EU Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for nasal glucagon. If the drug receives approval, it will be the first dry powder nasal spray on market to treat severe hypoglycemia.
https://beyondtype1.org/lilly-files-for-fda-approval-of-nasal-glucagon/
https://beyondtype1.org/lilly-files-for-fda-approval-of-nasal-glucagon/